Literature DB >> 11336117

Tobacco use and oral leukoplakia.

J Bánóczy1, Z Gintner, C Dombi.   

Abstract

The increase in cancer mortality throughout the world justifies the study of its causes and development. Hungary has the highest mortality rate from oropharyngeal cancer out of forty-six countries. Tobacco use is implicated in the development of oral cancer, and oral leukoplakia as well. The aim of the study was to give an overview of the connection between tobacco use and oral leukoplakia, considering the epidemiologic patterns of tobacco habits, the prevalence of smoking in oral leukoplakia, and the effect of smoking on clinically healthy oral mucosa with special respect to central Europe and Hungary. In the data, strong evidence has been found for the role of smoking in the development of both oral cancer and oral leukoplakia. Epidemiologic patterns of cigarette smoking show a steep increase in central European countries. Cross-sectional studies show a higher prevalence rate of leukoplakia among smokers, with a dose-response relationship between tobacco use and oral leukoplakia, and intervention studies show a regression of the lesion after stopping the smoking habit.

Entities:  

Mesh:

Year:  2001        PMID: 11336117

Source DB:  PubMed          Journal:  J Dent Educ        ISSN: 0022-0337            Impact factor:   2.264


  21 in total

1.  Smoking and drinking in relation to oral cancer and oral epithelial dysplasia.

Authors:  Douglas E Morse; Walter J Psoter; Deborah Cleveland; Donald Cohen; Mireseyed Mohit-Tabatabai; Diane L Kosis; Ellen Eisenberg
Journal:  Cancer Causes Control       Date:  2007-07-24       Impact factor: 2.506

2.  A video feedback-based tobacco cessation counselling course for undergraduates-preliminary results.

Authors:  M Antal; A Forster; Z Zalai; K Barabas; J Spangler; G Braunitzer; K Nagy
Journal:  Eur J Dent Educ       Date:  2012-08-14       Impact factor: 2.355

3.  Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma.

Authors:  Elizabeth J Franzmann; Erika P Reategui; Lutecia H Mateus Pereira; Felipe Pedroso; Debbie Joseph; Glenn O Allen; Kara Hamilton; Isildinha Reis; Robert Duncan; W Jarrard Goodwin; Jennifer J Hu; Vinata B Lokeshwar
Journal:  Head Neck       Date:  2011-07-11       Impact factor: 3.147

4.  Association between oral leukoplakia and upper gastrointestinal cancers: a 28-year follow-up study in the Linxian General Population Trial.

Authors:  J-H Fan; J-B Wang; C-X Qu; Y-Q Zhang; P R Taylor; C C Abnet; S M Dawsey; Y-L Qiao
Journal:  Oral Oncol       Date:  2014-08-11       Impact factor: 5.337

Review 5.  Precancerous lesions of oral mucosa.

Authors:  Gurkan Yardimci; Zekayi Kutlubay; Burhan Engin; Yalcin Tuzun
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

6.  Peroxiredoxin 1 has an anti-apoptotic role via apoptosis signal-regulating kinase 1 and p38 activation in mouse models with oral precancerous lesions.

Authors:  Jianfei Zhang; Xinying Jing; Wenwen Niu; Min Zhang; Lihua Ge; Congcong Miao; Xiaofei Tang
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

7.  Smoking as a risk factor for oral candidiasis in HIV-infected adults.

Authors:  Amit Chattopadhyay; Lauren L Patton
Journal:  J Oral Pathol Med       Date:  2012-12-04       Impact factor: 4.253

8.  Prevalence of oral Candida carriage and Candida species among cigarette and maras powder users.

Authors:  Hamit Sirri Keten; Derya Keten; Huseyin Ucer; Fatis Yildirim; Hakan Hakkoymaz; Oguz Isik
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 9.  Paying more than lip service to lip lesions.

Authors:  Janna M Bentley; Benjamin Barankin; Gilles J Lauzon
Journal:  Can Fam Physician       Date:  2003-09       Impact factor: 3.275

10.  The precancer risk of betel quid chewing, tobacco use and alcohol consumption in oral leukoplakia and oral submucous fibrosis in southern Taiwan.

Authors:  C-H Lee; Y-C Ko; H-L Huang; Y-Y Chao; C-C Tsai; T-Y Shieh; L-M Lin
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.